A sponsored-style explainer from telehealth provider Mochi Health on what the end of shortages means for compounded semaglutide and tirzepatide.
Recap by typeshit. Full story at Florida Today.
Keltie Knight shares a personal take on body image pressure on women, tagged with GLP-1 and BookTok. It's a short social clip with few specifics.
8:41
The weekly tirzepatide update marks a milestone for the channel, with the scale finally dipping below 220 pounds.
Dr. Salas-Whalen makes the case that stepping down on a GLP-1 dose can be as important as going up. Her view, not a protocol.
A short link post on what patients should keep in mind as options for semaglutide and tirzepatide keep shifting. Details are at the source.
PennLive reports regulators bumped the risk class on a GLP-1 recall involving an ingredient linked to Mounjaro and Zepbound. Details are at the link.
The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
Loading…